Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718135 | 0.87 | PPARG (0.46) | CYSLTR2CYSLTR1CNR1CNR2PPARG | |
| SCHEMBL585410 | 0.84 | TSHR (0.44) | — | |
| SCHEMBL2199999 | 0.84 | TSHR (0.44) | — | |
| SCHEMBL8568139 | 0.81 | CYSLTR2 (0.59) | CYSLTR2CYSLTR1FAAHALDH2MAOA | |
| SCHEMBL15798175 | 0.79 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1FAAHALDH2MAOA | |
| SCHEMBL584885 | 0.77 | TSHR (0.50) | — | |
| SCHEMBL3173429 | 0.77 | CYSLTR2 (0.60) | CYSLTR2CYSLTR1FAAHPDE3BPDE3A | |
| SCHEMBL19718155 | 0.77 | PPARA (0.47) | CYSLTR2CYSLTR1PDE3BPDE3APPARG | |
| SCHEMBL19718117 | 0.76 | CYSLTR2 (0.47) | CYSLTR2CYSLTR1FAAHALDH2PDE3B | |
| SCHEMBL8907914 | 0.76 | SYK (0.46) | PDE3BPDE3AP2RY12PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC | 2019-06-20 | — | — | US | disclosed |
| EP-3471774-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | Oncoselect Therapeutics, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017218959-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | ONCOSELECT THERAPEUTICS, LLC (US) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | CYSLTR2 4385/4885CYSLTR1 4487/4885FAAH 4855/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | CYSLTR2 4385/4885CYSLTR1 4487/4885FAAH 4855/4885 |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | TK2, KIT, HCCS | CYSLTR2 4070/4885CYSLTR1 4169/4885FAAH 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.